A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: Toward improving individualized cancer care Journal Article


Authors: Abu-Rustum, N. R.; Zhou, Q.; Gomez, J. D.; Alektiar, K. M.; Hensley, M. L.; Soslow, R. A.; Levine, D. A.; Chi, D. S.; Barakat, R. R.; Iasonos, A.
Article Title: A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: Toward improving individualized cancer care
Abstract: Objectives: Traditionally we have relied mainly on final FIGO stage to estimate overall oncologic outcome in endometrial cancer patients. However, it is well known that other patient factors may play equally important roles in outcome. Our objective was to develop a clinically useful nomogram in the hope of providing a more individualized and accurate estimation of overall survival (OS) following primary therapy. Methods: Using a prospectively maintained endometrial cancer database, 1735 patients treated between 1993 and 2008 were analyzed. Characteristics known to predict OS were collected. For each patient, points were assigned to each of these 5 variables. A total score was calculated. The association between each predictor and the outcome was assessed by multivariable modeling. The corresponding 3-year OS probabilities were then determined from the nomogram. Results: The median age was 62 years (range, 25-96). Final grade included: G1 (471), G2 (622), G3 (634), and missing (8). Stage included: IA (501), IB (590), IC (141), IIA (36), IIB (75), IIIA (116), IIIB (6), IIIC (135), IVA (7), and IVB (128). Histology included: adenocarcinoma (1376), carcinosarcoma (100), clear cell (62), and serous (197). Median follow-up for survivors was 29.2 months (0-162.2 months). Concordance probability estimator for the nomogram is 0.746 ± 0.011. Conclusion: We developed a nomogram based on 5 easily available clinical characteristics to predict OS with a high concordance probability. This nomogram incorporates other individualized patient variables beyond FIGO stage to more accurately predict outcome. This new tool may be useful to clinicians in assessing patient risk when deciding on follow-up strategies. © 2009 Elsevier Inc. All rights reserved.
Keywords: adult; cancer survival; human tissue; treatment outcome; aged; aged, 80 and over; middle aged; survival rate; major clinical study; overall survival; cancer risk; cancer patient; cancer staging; outcome assessment; follow up; endometrial cancer; staging; endometrium carcinoma; endometrial neoplasms; lymph nodes; cancer grading; diagnostic accuracy; endometrium cancer; prospective study; disease association; cancer survivor; patient care; nomograms; models, statistical; clinical evaluation; scoring system; predictor variable; clear cell carcinoma; databases, factual; nomogram; cystadenocarcinoma; carcinosarcoma
Journal Title: Gynecologic Oncology
Volume: 116
Issue: 3
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2010-03-01
Start Page: 399
End Page: 403
Language: English
DOI: 10.1016/j.ygyno.2009.11.027
PROVIDER: scopus
PMCID: PMC3870336
PUBMED: 20022094
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard R Barakat
    629 Barakat
  2. Dennis S Chi
    707 Chi
  3. Kaled M Alektiar
    333 Alektiar
  4. Douglas A Levine
    380 Levine
  5. Qin Zhou
    253 Zhou
  6. Alexia Elia Iasonos
    362 Iasonos
  7. Martee L Hensley
    289 Hensley
  8. Robert Soslow
    793 Soslow
  9. Jacob Daniel Gomez
    6 Gomez